Teleflex EBITDA
EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Teleflex (TFX) pr. 30. mar. 2026 er 545,74 Bio. USD. I foregående år var EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) 562,71 Bio. USD — en ændring på -3,02 % (lavere).
Get this data via API
Financial Data API
EBITDA
545,74 Bio.USD
YoY
-3,02%
Senest opdateret:
EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Teleflex er 2026 545,74 Bio. USD. EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Teleflex var 2025 562,71 Bio. USD. Det falder dermed med -3,02% lavere sammenlignet med året før.
Access this data via the Eulerpool API
Teleflex Aktieanalyse
Hvad laver Teleflex? Teleflex Inc. is a global company founded in 1943. The company is headquartered in Wayne, Pennsylvania, USA and operates in over 40 countries worldwide. It is a leading provider of medical devices, instruments, and accessories for various applications in clinical practice and patient care.
The business model of Teleflex is based on the manufacturing and marketing of medical devices and instruments, particularly in the areas of anesthesia, vascular access, interventional medicine, pulmonary and thoracic surgery, urological care, cardiovascular diagnostics, and surgery. The company works closely with medical professionals and clinicians to develop high-quality products that meet the needs of patients and doctors.
Teleflex is divided into several business segments, including angiography/diagnostics, anesthesia, oncology, vascular intervention, pulmonology, surgery, and urology. Each of these segments offers a wide range of products and solutions specifically tailored to the needs of doctors and patients.
In the angiography/diagnostics segment, Teleflex offers a variety of products that can be used for the diagnosis and treatment of cardiovascular diseases and other medical conditions. These include catheters, guide wires, and sheaths.
The anesthesia segment of Teleflex includes products such as ventilation bags, endotracheal tubes, and nebulizer systems. These products are essential for the successful performance of anesthesia procedures and can help doctors save valuable time and resources.
The oncology segment of Teleflex offers a wide range of products specifically designed for the treatment of cancer patients. These include catheter-based systems that can facilitate the administration of drugs and other therapies.
With the vascular intervention segment, Teleflex offers a comprehensive range of products and solutions specifically designed for the treatment of vascular diseases. These include balloon catheters, stents, and sheaths.
The pulmonology segment of Teleflex offers products aimed at facilitating breathing and improving the quality of life for patients with chronic respiratory diseases. These include oxygen concentrators, tracheal tubes, and ventilators.
The surgical segment of Teleflex offers a variety of solutions for performing surgical procedures, including surgical instruments, sutures, and wound care materials.
The urology segment of Teleflex offers a wide range of products specifically designed for use in urology. These include catheters, wires, and stents.
Teleflex is a leading company in the medical technology industry that specializes in the development and marketing of products that improve patients' quality of life and facilitate the work of doctors. With its innovative solutions and a focus on providing the best possible customer service and patient safety, Teleflex has taken on a significant role in the industry and will continue to be an important provider in this market in the future. Teleflex er et af de mest populære virksomheder på Eulerpool.com.
Hyppigt stillede spørgsmål om Teleflex aktie
EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) af Teleflex var 562,71 Bio. USD 545,74 Bio.
Access this data via the Eulerpool API
Resultatopgørelse — Teleflex
Alle nøgletal — Teleflex
Værdiansættelse
Resultatopgørelse
Marginer
Balance
- Samlede aktiver
- Omsætningsaktiver
- Likvide midler
- Tilgodehavender
- Lagerbeholdning
- Materielle anlægsaktiver
- Goodwill
- Immaterielle aktiver
- Egenkapital
- Forpligtelser
- Gæld
- Kortfristede gældsforpligtelser
- Langfristet gæld
- Kortfristet gæld
- Tilbageholdt overskud
- Bogført værdi pr. aktie
- Materiel bogført værdi pr. aktie
- Arbejdskapital
- Investeringer
- Leverandørgældsforpligtelser
- Anlægsaktiver
- Kortfristede investeringer
- Langfristede investeringer
- Nettogæld
- Egne aktier
- Minoritetsinteresser
- Udskudt skatteforpligtelse
- Netto materielle aktiver
- Goodwill/Aktiver
- Immaterielle aktiver/Aktiver
Pengestrøm
- Operativt cash flow
- Investeringsudgifter
- Frit cash flow
- FCF pr. aktie
- Udbetalt udbytte
- Aktietilbagekøb
- Investeringscash flow
- Finansieringscash flow
- CapEx/Omsætning
- Cash flow pr. aktie
- Aktiebaseret kompensation
- Ændring i arbejdskapital
- Akquisitioner (netto)
- Netto likviditetsændring
- CapEx/OCF
- FCF/Resultat
- FCF-konvertering
- Likviditetskonvertering
- Samlet aktionærudbetaling
- CapEx/Afskrivninger
Rentabilitet
- ROE
- ROA
- ROCE
- ROIC
- Aktivomsætning
- Lageromsætning
- Tilgodehavendeomsætning
- Dage til betaling af salg
- Dage for lagerbeholdning
- Dage skyld til betaling
- Cash conversion cycle
- CROIC
- Bruttoavance/Aktiver
- Omsætning af anlægsaktiver
- Egenkapitalomsætning
- Arbejdskapitalomsætning
- Gældsomveksling
- Kapitalintensitet
- Tilgodehavender/Omsætning
- Lagerbeholdning/Omsætning
- EBIT/Aktiver
Gearing
Vækst
- Omsætningsvækst
- Omsætningsvækst 3-årigt CAGR
- Omsætningsvækst 5-årigt CAGR
- Omsætningsvækst 10-årigt CAGR
- Driftsvækst
- EPS-vækst
- EBIT-vækst
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividendevækst
- FCF-vækst
- Bogført værdi-vækst
- Resultaatvækst CAGR 3Y
- Resultaatvækst CAGR 5Y
- Resultaatvækst CAGR 10Y
- EPS-vækst CAGR 3Y
- EPS-vækst CAGR 5Y
- EBITDA-vækst YoY
- EBITDA-vækst CAGR 3Y
- EBITDA-vækst CAGR 5Y
- Bruttoavancevækst
- OCF-vækst YoY
- Medarbejdertilvækst
- Dividend CAGR 3år
- Dividend CAGR 5år
- Dividend CAGR 10år
- Aktivvækst
- Egenkapitalvækst
- Gældsværkst
- CapEx-vækst
- FCF CAGR 3år
- FCF CAGR 5år
- Markedsværdivækst
- Aktievækst